PuSH - Publication Server of Helmholtz Zentrum München

Lutz, S.Z. ; Ullrich, A.* ; Häring, H.-U. ; Ullrich, S. ; Gerst, F.

Sunitinib specifically augments glucose-induced insulin secretion.

Cell. Signal. 36, 91-97 (2017)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
The tyrosine kinase inhibitor sunitinib is used for the treatment of numerous cancers in humans. In diabetic patients, sunitinib lowers blood glucose levels and improves glycaemic control. This study aims to analyse whether sunitinib has specific and direct effects on insulin secreting β-cells. Regulation of insulin secretion, of cellular cAMP levels and activation of signalling pathways were examined upon exposure of rat insulinoma INS-1E cells to sunitinib under specific stimulatory and inhibitory conditions. Secreted insulin and cellular cAMP levels were measured using RIA and ELISA, respectively. Protein phosphorylations were examined on western blots. Sunitinib enhanced glucose-induced insulin secretion (GIIS) concentration-dependently, reaching a maximal stimulation at 2μM. Sunitinib further augmented insulin secretion in the presence of elevated cAMP levels and the FFAR1 agonists. Adrenaline and the PKA inhibitor H89 counteracted the stimulatory effect of sunitinib on secretion. However, sunitinib altered neither the cellular levels of cAMP nor the phosphorylation of PKA. Sunitinib did not reduce IGF-1-induced phosphorylation of AKT/PKB and ERK1/2. In conclusion, these results suggest that sunitinib stimulates GIIS by a direct effect on β-cells, which may contribute to the glucose-lowering action of the tyrosine kinase inhibitor in humans.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Ffar1 ; Glp-1r ; Insulin Secretion ; Pka ; Sunitinib ; Camp; Pancreatic Beta-cells; Acid Receptor 1; Tyrosine Phosphorylation; In-vitro; Vegf-a; Islets; Mice; Activation; Protects; Death
ISSN (print) / ISBN 0898-6568
e-ISSN 0898-6568
Journal Cellular Signalling
Quellenangaben Volume: 36, Issue: , Pages: 91-97 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place New York
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes Research and Metabolic Diseases (IDM)